Idhifa (enasidenib mesylate) is a small molecule pharmaceutical. Enasidenib mesylate was first approved as Idhifa on 2017-08-01. It is used to treat myeloid leukemia acute in the USA. Idhifa's patents are valid until 2034-09-16 (FDA).
|Common Name||Enasidenib mesylate|
|Indication||myeloid leukemia acute|
|Drug Class||Mutated isocitrate dehydrogenase (IDH) inhibitors|